![American Society of Clinical Oncology American Society of Clinical Oncology](https://54d4f314-8f94-415c-acb7-fd0a6332f070.s3.amazonaws.com/403/403__asco-logo-lg__274272709.png?X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAU2BE4PNFKE2WZV7V%2F20240727%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20240727T055309Z&X-Amz-SignedHeaders=host&X-Amz-Expires=86400&X-Amz-Signature=49de7ce656d794c19906f1b121c3d9c1a9192d31cadee19dd89bd0917d7408c0)
Advanced Gastroesophageal Cancer
Publication Date: January 5, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...reatment...
...gure 1. Immunotherapy and Targeted Ther...
First-line Ther...
...1.1For HER2-negative patients with gastric a...
...commendation 1.2For HER2-negative patients...
...ion 1.3For patients with ESCC and PD-L1 CPS...
...mmendation 1.4For patients with ESCC, and PD...
...ndation 1.5For patients with HER2-positive...
...cond- or Third-line...
...ation 2.1For patients with advanced gastroesophage...
Recommendation 2.2For HER2-positive...